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Abstract: p140Cap is an adaptor protein that negatively controls tumor cell properties, by inhibiting in vivo tumor 
growth and metastasis formation. Our previous data demonstrated that p140Cap interferes with tumor growth and 
impairs invasive properties of cancer cells inactivating signaling pathways, such as the tyrosine kinase Src or E-cad-
herin/EGFR cross-talk. In breast cancer p140Cap expression inversely correlates with tumor malignancy. p140Cap 
is composed of several conserved domains that mediate association with specific partners. Here we focus our at-
tention on two domains of p140Cap, the TER (Tyrosine Enriched Region) which includes several tyrosine residues, 
and the CT (Carboxy Terminal) which contains a proline rich sequence, involved in binding to SH2 and SH3 domains, 
respectively. By generating stable cell lines expressing these two proteins, we demonstrate that both TER and CT 
domains maintain the ability to associate the C-terminal Src kinase (Csk) and Src, to inhibit Src activation and Focal 
adhesion kinase (Fak) phosphorylation, and to impair in vitro and in vivo tumor cell features. In particular expression 
of TER and CT proteins in cancer cells inhibits in vitro and in vivo growth and directional migration at a similar extent 
of the full length p140Cap protein. Moreover, by selective point mutations and deletion we show that the ability of 
the modules to act as negative regulators of cell migration and proliferation mainly resides on the two tyrosines (Y) 
inserted in the EPLYA and EGLYA sequences in the TER module and in the second proline-rich stretch contained in 
the CT protein. Gene signature of cells expressing p140Cap, TER or CT lead to the identification of a common pat-
tern of 105 down-regulated and 128 up-regulated genes, suggesting that the three proteins can act through shared 
pathways. Overall, this work highlights that the TER and CT regions of p140Cap can efficiently suppress tumor cell 
properties, opening the perspective that short, defined p140Cap regions can have therapeutic effects.
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Introduction
The p140Cap adaptor protein has been recent-
ly involved in tumor progression, as a negative 
regulator of integrin and growth factor-depen-
dent carcinoma cell properties (for a review 
[1]). Screening of mammary breast cancers by 
IHC revealed that p140Cap expression in 
human breast tumours inversely correlates 
with tumour malignancy. Indeed p140Cap is 
expressed in 41% of tumor specimens charac-
terized by G1/G2 index, as well in 41% of node 
negative patients. The percentage of p140Cap 
positive samples drops to 5% in G3 tumors and 
to 10% in node positive tumors [2], thus sug-
gesting that p140Cap may contribute at least to 
slow tumor progression.
The p140Cap modular structure contains a 
Tyrosine Enriched Region (TER) which includes 
several tyrosine residues, a coil-coiled domain, 
two regions rich in charged amino acids, and a 
Carboxy Terminal which contains a proline rich 
sequence (CT) [3, 4]. p140Cap was originally 
identified to bind through coil-coiled interac-
tions to the synaptic membrane protein SNAP-
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25 [3], and, through the proline-rich region in 
the CT region, to Src kinase [5], Vinexin [6], and 
Cortactin [7, 8]. The CT domain of p140Cap 
also associates to EB3, a member of the micro-
tubule plus-end tracking protein EB family [7]. 
Moreover, p140Cap directly binds Csk [5], 
through tyrosine residues inserted in the TER 
region, namely the sequences EPLYA and 
EGLYA, that associate to the Csk SH2 domain 
[9]. In the presence of p140Cap, Csk is more 
active and phosphorylates the inhibitory tyro-
sine on the C-terminal domain of Src allowing 
the closure of Src in an inactive conformation 
[5]. Overall p140Cap behaves as a molecular 
hub that may negatively control signaling, like 
the Src kinase activation, through direct asso-
ciation with specific partners.
Since it is increasingly interesting understand-
ing how a cancer cell can be controlled from 
networks originating from modular domains 
present in “hub” proteins [10], we further dis-
sected the functional role of specific regions of 
p140Cap, focusing on the TER and the CT 
regions. We show here that the TER (Tyrosine 
Enriched Region) and the CT regions retain the 
ability to associate Csk and Src and mimic full 
length p140Cap properties in down-regulating 
Src kinase activity and the tumourigenic fea-
tures of different cancer cell lines. By mutating 
EGLYA and EPLYA tyrosine residues in the TER 
domains, and deleting the proline rich region in 
CT we highlighted the contribution of these resi-
dues to the inhibition of tumourigenic proper-
ties of breast cancer cells. Microarray analysis 
shows that p140Cap, TER and CT expressing 
cells share a great number of genes down- and 
up-regulated, implying that these three pro-
teins can use common pathways for affecting 
tumor features.
Material and methods
Cell lines, reagents and antibodies
Human breast (MDA-MB-231) and colon (HT-
29) carcinoma cell lines were obtained from 
ATTC and cultured in DMEM with 10% Fetal Calf 
Serum (FCS) and Penicillin/Streptomycin as 
previously described [2, 5, 8]. Antibodies to the 
activated Src (pSrc Y416), tyrosine phosphory-
lated Fak (pFak Y925) and vimentin were pur-
chased from Cell Signaling (Beverly MA); anti-
bodies to Src, Vinculin and Csk were from Santa 
Cruz Biotechnology (SantaCruz, CA). p140Cap 
monoclonal and polyclonal antibodies, GFP and 
Fak monoclonal polyclonal antibodies were pro-
duced in our laboratory as previously described 
[4]. Glutathione-Sepharose, Protein A-Sepha- 
rose, Protein G-Sepharose, Horse radish per-
oxidase, nitrocellulose and films were from GE 
Healthcare Bio-Science AB. Tissue culture 
media, serum and antibiotics, LTX lipo-
fectamine, and neomycine (G418) were from 
Invitrogen. Matrigel was from Becton Dickinson.
Preparation of cDNA constructs and genera-
tion of stable populations of expressing cells
The CT construct was generated by digesting 
the full length p140Cap cDNA with NheI/XbaI 
restriction enzymes and by cloning the frag-
ment in pEGFP N1. The TER construct was pre-
pared by digesting the full length p140Cap 
cDNA with PstI enzyme and by cloning in pEGFP 
N1.
The mutants construct PG-TER encoding for the 
double point mutation of TER tyrosines 264 
and 396 into phenylalanine (Y/F) was obtained 
by digesting with Pst1 the PG-FL p140Cap con-
struct already described in [9]. The DeltaPro-CT 
was prepared by digesting with NheI and XbaI 
the DeltaPro-FLp140Cap already described in 
[5].
The different constructs were stably transfect-
ed in carcinoma cell line using Lipofectamine 
LTX, according to manufacturer’s instruction 
(Invitrogen). For selection 800 microgram/ml of 
G418 (Gibco) were used and GFP-positive cells 
were sorted using fluorescence activated cell 
sorting machine.
Protein expression analysis
To analyse protein expression, cells were deter-
gent extracted with lysis buffer (50 mM HEPES 
(pH 7.5), 150 mM NaCl, 1.5 mM MgCl, 1 mM 
EDTA, 1% Triton X-100, and 10% glycerol) con-
taining protease and phosphatase inhibitors (1 
mM PMSF, 10 mg/ml leupeptin, 10 mg/ml 
aprotinin, 100 mM NaF, and 200 mM NaVO4). 
The supernatants were collected and assayed 
for protein concentration using the Bio-Rad pro-
tein assay method (Bio-Rad). Fifty micrograms 
cell extracts were mixed with Laemmli’s sample 
buffer, and boiled for 10 min. After 6% SDS-
PAGE, proteins were electrophoretically trans-
ferred to nitrocellulose (Amersham, Arlington 
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Heights, IL) and check for the protein expres-
sion using anti GFP monoclonal antibody.
For immunoprecipitation, Dynabeads (Invitro- 
gen) were cross linked with the specific anti-
body, following manufacture protocol. Cell 
extracts (2 mg) were incubated with the 
Dynabeads-conjugated antibodies for two 
hours at 4°C. The immunoprecipitates were 
washed three times with 1 ml of lysis buffer, 
resolved on SDS-PAGE, transferred onto nitro-
cellulose and reacted with specific antibodies. 
As input, fifty micrograms of cell extracts were 
analysed by SDS-PAGE and Western Blotting.
For serum stimulation, confluent cells were 
starved overnight and stimulated with 20% FCS 
for 30 min.
Directional cell migration assay
For directional cell migration assays, Transwell 
chambers were coated with 10 microgram/ml 
fibronectin. A total of 5 x 104 cells were seeded 
on the upper side of the filters and left to 
migrate for 2 hr in presence or absence of 20% 
FCS. Cells migrating to the lower side were fixed 
and stained with Diff-Quick kit. The mean num-
ber of migrated cells was counted in 10 ran-
dom fields.
Cell proliferation and soft agar assays
A total number of 1 x 104 stably transfected 
cells were seeded on 12 wells tissue culture 
dishes in the presence of culture medium. 
Every 2 days, cells were detached and manually 
counted in Burker chambers on triplicate wells. 
For the clonogenic assay, 5 x 105 cells were 
seeded in 0.35% agar on the top of a base layer 
containing 0.7% agar into six-well plates. After 
3 weeks, colonies were counted in four random 
fields under a phase-contrast microscope at 
20X magnification. All of the experiments were 
performed in triplicate.
In vivo tumor growth
Five week old female SCID mice were pur-
chased from Charles River Laboratories (Calco, 
Italy) and treated in accordance with the 
European Community guidelines. 10 x 107 
MDA-MB-231 or 1 x 106 HT-29 cells were mixed 
with 150 microliters DMEM and 150 microliters 
Matrigel and then injected subcutaneously into 
the left and right inguinal region of female SCID 
mice. The size of the tumors was evaluated 
twice weekly using calipers. In all the in vivo 
tumor growth experiment, the investigators 
were blind to the cell type the animal received. 
All the in vivo experiments were repeated three 
times. Tumor volumes were analyzed with the 
Anova test.
Gene expression analysis
Total RNA was isolated from cells using 
Absolutely RNA mRNA kit (Agilent Technologies, 
Palo Alto, CA). mRNA was amplified and labeled 
by Amino Allyl MessageAmp II aRNA Kit (Ambion, 
Austin, TX) using NHS ester Cy3 dye (Amersham 
Biosciences, Arlington Heights, IL). Total RNA 
quality and labeling was checked by means of 
RNA 6000 Nanochip assays and run on the 
Agilent 2100 Bioanalyzer (Agilent Technologies, 
Santa Clara, CA). Total RNA, amplified and 
labeled mRNA concentrations were calculated 
using the NanoDrop ND-1000 Spectro- 
photometer (NanoDrop Technologies, Wilming- 
ton, DE).
Equal amounts (0.2 microgram) of labeled 
specimens were fragmented and hybridized to 
Human Whole Genome Oligo Microarrays 
8x60K (Agilent Technologies). Each step was 
performed using the In Situ Hybridization Kit-
Plus (Agilent Technologies) and following the 
60-mer oligo microarray processing protocol. 
Slides were then washed with the SSPE wash 
procedure and scanned using an Agilent C 
dual-laser microarray scanner.
Images were analyzed using Feature Extraction 
software v10.5 (Agilent Technologies) and raw 
data processed within R statistical environ-
ment, using the limma library. The raw intensity 
values were background corrected with meth-
od “normexp”, as provided by the function 
backgroundCorrect of the limma package. In 
order to have similar intensity distributions 
across all arrays, log2 transformed intensity 
values were then subjected to between array 
normalization with “quantile” method. For each 
condition, replicates were combined and the 
empirical Bayes method was applied to retrieve 
a list o modulated probes in treated vs control 
samples, using 0.01 as cut-off for the Benjamini-
Hochberg adjusted p-value and 1 for absolute 
log fold change. Venn diagrams to depict the 
commonly regulated genes by the three con-
structs (FL, CT and TER) were created with the 
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Figure 1. Expression of TER and CT modules affects MDA-MB-231 in vitro cell proliferation, migration, and Src and 
Fak phosphorylation. A. Schematic representation of p140Cap FL, NT, TER and CT protein structure. The position 
of relevant domains is indicated: Tyr = Tyrosine, Pro = Proline, C1/C2 coiled/coil, Ch = charged amino acids. The 
numbers indicate the amino acid position. B. Upper panels. To evaluate the association with Csk and Src, four mg 
extracts of MDA-MB-231 cells stably expressing Mock, NT, CT and FL p140Cap, all tagged with EGFP, were immuno-
precipitated with antibodies to GFP. ¾ of the material was run on 8% SD-PAGE and western blotted with antibodies 
to Csk and Src. Input: fifty micrograms of FL p140Cap cell extract. Lower panel. For quantification of GFP-tagged 
fusion proteins expression, the remaining immunoprecipitate was run on 6% SDS-PAGE and blotted with antibodies 
to GFP. C. For assessing cell proliferation, 1 x 104 cells were plated in 12 wells dishes in 10% FCS DMEM culture 
medium. Each second day cells three wells were detached and counted manually. The mean number of cells is rep-
resented by y-axis. The results are representative of three independent experiment. The data were evaluated with 
two-way ANOVA followed by Bonferroni multiple comparison post hoc tests (*P < 0.05; **P < 0.01; ***P < 0.001). 
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help of the on-line tool Venny (http://bioinfogp.
cnb.csic.es/tools/venny/index.html).
Gene Ontology enrichment analysis
GO analysis was done either separately or 
together for up and down-regulated genes. In 
this case, the filter on log fold change was not 
applied.
Each list of modulated probes was loaded on 
DAVID tool for functional annotation analysis 
(http://david.abcc.ncifcrf.gov/summary.jsp), 
using the Agilent Whole Genome Oligo 
Microarray 8x60K as background. The Gene 
Ontology Biological Processes level 5 (BP5) 
overrepresented in all the three conditions (FL, 
TER and CT) were identified and the union of 
the genes modulated in at least one condition 
and involved in each overrepresented BP5 was 
used to create expression matrices containing 
the log fold change of the expression of each 
gene in FL, TER and CT compared to MOCK. The 
matrices of the most interesting BP5 were 
selected and loaded in Tigr MultiExperiment 
Viewer (TmeV version 4.6.1, http://www.tm4.
org/mev/) to generate heatmaps by means of 
hierarchical clustering.
Results and discussion
The p140Cap TER and CT regions are suf-
ficient to down regulate in vitro tumor cell 
features.
MDA-MB-231 cells are known as an aggressive 
model of basal-like breast cancer [11], and do 
not express endogenous p140Cap, thus repre-
senting an ideal model to evaluate whether 
exogenous expression of p140Cap or of its 
domains can suppress their intrinsic tumouri-
genic properties. We have already shown that 
expression of p140Cap in these cells suppress 
in vivo tumor growth [5]. In order to assess the 
ability of specific domains of p140Cap to nega-
tively control tumor features, we stably 
expressed in MDA-MB-231 breast cancer cells 
constructs encoding for the tyrosine enriched 
region (TER) (from amino acids 221 to 487), 
and the C-terminal (CT) part of p140Cap (from 
aa 694 to aa 1153), as well as the p140Cap full 
length (FL), as fusion proteins with EGFP (Figure 
1A). Empty vector expressing EGFP was used 
as a positive control (Mock). As shown in Figure 
1B, immunoprecipitation experiments with 
antibodies to GFP revealed that Mock, TER, CT 
and FL expressing cells produced GFP-fusion 
proteins of the expected molecular weight (30, 
57, 97 and 170 kDa, respectively) (Figure 1B, 
lower panels). As expected, the FL protein co-
immunoprecipitated both Src and Csk [4, 5, 9]. 
The TER and CT protein retain the ability to 
associate Csk and Src, respectively, likely 
through the Csk and Src binding domains previ-
ously identified in the FL (Figure 1B, upper pan-
els). Interestingly the TER protein also immuno-
precipitated Src, suggesting that the TER region 
could also associate Src. This binding might be 
due either to direct association of the Src SH2 
domain with a tyrosine residue inserted in the 
TER region, or indirectly through Csk. Therefore, 
the TER and CT regions, expressed as such, still 
retain a molecular conformation that confers 
the ability to associate with Src and Csk at a 
similar extent than the FL protein.
p140Cap has been identified as a critical regu-
lator of in vitro cell proliferation and migration 
of breast cancer cells [2, 5, 8]. To assess the 
ability of TER and CT modules to interfere with 
cell proliferation, an equal number of Mock, 
TER, CT and FL expressing cells was plated in a 
12 well plate and counted every 48 hours for 
10 days. As shown in Figure 1C, cells over-
expressing FL exhibited a significant decrease 
in cell proliferation compared with Mock cells. 
Both TER and CT cells showed an inhibition of 
cell proliferation comparable to that observed 
in FL expressing cells.
Motility is a fundamental property of cancer 
cells that escape from the primary tumor and 
D. For assessing cell migration, cells were starved overnight, detached and plated (5 x 104) on fibronectin-precoated 
Transwells. Cells were allowed to migrate with or without 20% FCS for 2 hours. Cells migrating to the lower side were 
fixed and stained with Diff-Quick kit. The mean number of migrated cells was counted in 10 random fields. Mean 
values were calculated on five independent experiment. The data were evaluated with one-way ANOVA followed by 
Bonferroni multiple comparison post hoc tests (*P < 0.05; **P < 0.01; ***P < 0.001). E. Cells were starved over 
night and treated with  20% FCS for 30 min. Cell extracts were run on 8% SDS-PAGE and western blotted with an-
tibodies to the activated Src (pSrc Y416), Src, tyrosine phosphorylated Fak (pFak Y925) and Fak. The histograms 
show the ratio between phosphorylated and total amount of protein in arbitrary units. (*P < 0.05, Student’s t-test; 
** P < 0.01).
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invade into new tissues. To test directional 
migration in transwell assays, Mock, TER, CT 
and FL expressing cells were plated on fibro-
nectin-coated Transwells and allowed to 
migrate towards serum for 2 hours. The mean 
of three experiments (Figure 1D) showed that 
upon stimulus TER and CT expressing cells 
migrated significantly less than Mock cells, as 
FL expressing cells. The difference in cell migra-
tion was not dependent on cell adhesion, since 
the number of cells adherent to fibronectin was 
similar in the four cell subtypes (data not 
shown). The data presented here indicate that 
in MDA-MB-231 cells the TER and CT regions 
are capable of interfering with in vitro tumor 
cell proliferation and migration at a similar 
extent than the FL protein.
TER and CT domains impair Src activation and 
Fak phosphorylation
Growth factor treatment as well as integrin-
mediated adhesion leads to Src kinase activa-
tion which results in phosphorylation of Fak on 
the tyrosine (Y) 925 [12, 13]. We have previ-
ously shown that p140Cap over-expression 
inhibits Src activation leading to reduced Fak 
phosphorylation [2, 5]. To assess the ability of 
TER and CT domains to regulate cell signaling, 
MDA-MB-231 cells expressing Mock, TER, CT 
and FL proteins were starved overnight and 
treated with or without serum for 30 minutes. 
Cell extracts were evaluated with antibodies to 
the activated Src (pSrc Y416), and tyrosine 
phosphorylated Fak (pFak Y925). As expected 
[5], cells over expressing FL p140Cap were pro-
foundly inhibited in Src activation, and in Fak 
tyrosine phosphorylation (Figure 1E, upper 
panels), both at basal and stimulated level, 
compared to Mock cells. Remarkably, cells 
expressing TER and CT proteins also presented 
a similar strong down-regulation of Src activa-
tion and consequently of Fak phosphorylation. 
Densitometric analysis of three independent 
experiments (Figure 1E, lower panels) show 
that the extent of TER and CT-mediated inhibi-
tion of Src and Fak phosphorylation is quite 
similar to that of FL expressing cells, indicating 
that TER, CT and FL p140Cap proteins share 
the ability to interfere with Src signaling.
So far p140Cap function in tumor epithelial 
cells has been mostly associated to its ability to 
inhibit Src kinase, indicating that p140Cap 
expression in tumors can rewire Src signaling 
‘circuits’ resulting in inhibition of growth and 
metastasis formation [5, 8]. Therefore the 
capability of the TER and CT domains to down-
regulate Src activity and Fak phosphorylation 
may represent a main mechanism through 
which these domains negatively affect tumor 
cell proliferation and migration. However, the 
ability of TER and CT proteins to down-regulate 
additional signaling pathways cannot be exclud-
ed and will be investigated in a next future.
Figure 2. Expression of TER and CT modules affects MDA-MB-231, and HT-29  in vivo tumor growth. A. 1 x 107 MDA-
MB-231 cells expressing TER, CT and FL p140Cap or Mock were mixed with Matrigel and injected subcutaneously in 
the two flanks of 5 week old female SCID mice.  Four mice for each cell type wahe size of the tumors was evaluated 
twice a week using caliper for 60 days.  B. 1 x 106 HT-29 cells over-expressing TER, CT and FL p140Cap or Mock were 
injected as in A. The size of the tumors was evaluated twice a week using calliper for 28 days. A-C: The results are 
representative of two independent experiments, with a number of six tumors for each cell type in each experiment. 
Differences in tumor volume were evaluated with two-way ANOVA followed by Bonferroni multiple comparison post 
hoc tests (*P < 0.05; **P < 0.01; ***P < 0.001).
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Figure 3. Expression of TER and CT mutants affects specific properties of TER and CT proteins. A. Left panel. 
Schematic representation of p140Cap FL, TER and CT protein structure and their respective mutants PG-TER and 
DeltaPro-CT. In PG-TER the tyrosines (Y) in 264 and 396 have been mutated in phenylalanine (F). In DeltaPro-CT 
a region spanning amino acid 1000-1048 has been deleted. Right panel. For quantification of GFP-tagged fusion 
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TER and CT domains profoundly impair in vivo 
tumor growth in breast and colon cancer cell 
lines
Forced expression of p140Cap in MDA-MB-231 
breast cancer cells strongly inhibits in vivo 
tumor formation [5]. In order to determine the 
respective role of TER and CT regions on in vivo 
tumor progression, immunocompromised mice 
were orthotopically injected with 1 x 107 Mock, 
TER, CT and FL MDA-MB-231 cells. As expected 
[5], Mock cells gave rise to tumors of 200 mm3 
volume within sixty days after subcutaneous 
injection, and FL expressing cells did not grow 
as detectable tumors (Figure 2A). Remarkably, 
injection of TER and CT expressing cells result-
ed in extremely reduced tumor growth. In par-
ticular, TER cells did not give rise to detectable 
tumors, while CT cells drastically delayed the 
appearance of tumors that at sixty days were 
very small (Figure 2A). Therefore both TER and 
CT regions retain the ability of FL p140Cap to 
profoundly modify tumor cell properties, down-
regulating in vivo tumor growth of this aggres-
sive breast cancer model.
To assess if the ability of TER and CT proteins to 
impair in vivo tumor growth is not restricted to 
a breast cancer model, but can be extended to 
other carcinoma cell types, we stably expressed 
the proteins in HT-29 cells, as a model of 
aggressive colon tumors. The levels of expres-
sion were comparable to that reached in MDA-
MB-231 cells (data not shown). Subcutaneously 
injected p140Cap FL expressing cells grew very 
poorly in vivo compared to Mock cells, and TER 
and CT expressing HT-29 cells behave like the 
FL cells (Figure 2B). These cells express an 
endogenous p140Cap protein whose silencing 
leads to cells that grow as tumors of increased 
volume compared with control cells [2], show-
ing that tuning p140Cap expression can pro-
foundly affect HT-29 tumor cell growth. The 
results presented here indicate that the expres-
sion of TER and CT proteins further strengthens 
the negative regulation of tumor growth exerted 
by the endogenous protein p140Cap FL. These 
data also suggest that TER, CT and FL proteins 
may share the ability to affect key pathways 
that both breast and colon tumor cells exploit 
for in vivo growth. Although we can not prove at 
this stage that TER and CT proteins use mecha-
nisms of inhibition common or alternative to 
those regulated by the FL protein, these data 
indicate that alone on in combination with the 
endogenous protein, the TER and CT proteins 
are highly effective for impairing in vivo growth 
of breast and colon carcinoma cells. 
Specific residues in the TER and CT domains 
contribute to inhibition of cell migration and 
tumor cell growth
The TER and CT proteins still span over hun-
dreds of amino acids, however they contain 
short amino acid stretches that on the basis of 
their binding capacities, might be sufficient for 
mediating the observed inhibition of tumor 
properties. In the FL protein, we have already 
demonstrated that mutation of the two tyrosine 
residues inserted in the EPLYA and EGLYA 
sequences impairs Csk binding [9]. Moreover, 
mutation of the carboxy-terminal consensus 
proline rich sequence SPPPPPPRRS affects Src 
proteins expression, 50 microgram cell extracts were run on 6% SDS-PAGE and blotted with antibodies to GFP.  B. 
To evaluate the association with Csk and Src, four mg extracts of MDA-MB-231 cells stably expressing the different 
GFP-tagged fusion proteins, were immunoprecipitated with antibodies to GFP, run on 8% SD-PAGE and western blot-
ted with antibodies to Src and Csk. Input: fifty micrograms of FL p140Cap cell extract. A lower exposure for Csk is 
shown on the right. C. For assessing cell proliferation, 1 x 104 cells were plated in 12 wells dishes in 10% FCS, DMEM 
culture medium. Each second day cells three wells were detached and counted manually. The mean number of cells 
is represented by y-axis. The results are representative of three independent experiments. Left panel: Mock, TER, 
PG-TER and FL. The data were evaluated with two-way ANOVA followed by Bonferroni multiple comparison post hoc 
tests (*P < 0.05; **P < 0.01; ***P < 0.001).  Mock cells were significantly different from TER, PG-TER and FL that 
do not differ each other.  Right panel: Mock, CT, DeltaPro-CT and FL. The data from Mock cells significantly different 
from CT anf FL, and not for DeltaPro-CT. D. For assessing anchorage-independent growth, Mock, TER, PG-TER, CT, 
DeltaPro-CT, and FL cells were plated in a soft agar assay and let to grow for three weeks. The bars represent the 
mean number of colonies for each cell type, as counted in four random fields under a phase-contrast microscope at 
20X magnification. The data were evaluated with one-way ANOVA followed by Bonferroni multiple comparison post 
hoc tests (*P < 0.05; **P < 0.01; ***P < 0.001). E. For assessing cell migration, Mock, TER, PG-TER, CT, DeltaPro-
CT, and FL cells were starved overnight, detached and plated (5 x 104) on fibronectin-precoated Transwells. Cells 
were allowed to migrate with or without 10% FCS for 2 hours. The mean number of migrated cells was counted in 10 
random fields. The data were evaluated with one-way ANOVA followed by Bonferroni multiple comparison post hoc 
tests (*P < 0.05; **P < 0.01; ***P < 0.001).
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Figure 4. Gene expression and Gene Ontology enrichment analysis. Total RNA was extracted from MDA-MB-231 cells 
expressing TER, CT, FL or Mock cells and hybridized to Human Whole Genome Oligo Microarray 8 x 60 K (Agilent 
Technologies). A. Venn diagrams to depict the commonly regulated genes by expression of the three constructs (FL, 
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binding [5]. To assess whether these sequenc-
es have a key role in suppressing tumor proper-
ties in the context of the TER and CT modules, 
the TER cDNA was mutated in the EPLYA and 
EGLYA tyrosines (PG-TER) and the CT was delet-
ed of the proline rich region (from amino acids 
1000 to 1048) (DeltaPro-CT) (Figure 3A). 
Expression of the corresponding proteins in 
MDA-MB-231 cells was confirmed by western 
blot (Figure 3B, left panel). As shown in Figure 
3B, right panel,  the DeltaPro-CT and the 
PG-TER mutants did no longer immunoprecipi-
tate Src and both Csk and Src, respectively, 
indicating that these specific mutations disrupt 
these binding capabilities.
For assessing cell proliferation, anchorage-
dependent and independent assays were used. 
When an equal number of Mock, TER, PG-TER, 
CT, DeltaPro-CT and FL expressing cells was 
plated in a 12 well plate and counted every 48 
hours for 10 days, the DeltaPro-CT mutant grew 
at the similar extent of Mock cells, rescuing cell 
proliferation compared to the CT expressing 
cells (Figure 3C, Right panel). Instead, the 
PG-TER mutant cells grew poorly as the TER 
cells and were not able to reach the Mock lev-
els (Figure 3C, Left panel).  Thus the proline 
rich domain is essential for inhibition of in vitro 
tumor cell proliferation, while the EPLYA and 
EGLYA motifs are not primarily involved in the 
control of this tumor feature. Interestingly, as 
shown in Figure 3D, when cells were tested for 
directional migration in transwell assays, the 
PG-TER expressing cells were capable to 
migrate like Mock cells, while the DeltaPro-CT 
cells migrate more than the CT cells, but signifi-
cantly less than Mock cells. These data indi-
cate that the tyrosines included in the EPLYA 
and EGLYA motifs, but not the proline-rich 
sequence, are key elements in the negative 
regulation of directional cell migration.
Cells were also plated in an anchorage-inde-
pendent manner in a soft agar assay, to reca-
pitulate the conditions where only aggressive 
tumor cells can survive and form colonies in the 
absence of adhesion. While consistently with 
previous data [5], FL expressing cells gave rise 
to a strong reduction in the number of colonies 
compared to Mock cells (Figure 3E), the expres-
sion of TER and CT proteins impaired colony 
formation, although to a lesser extent than FL. 
However this partial phenotype was rescued by 
expression of both PG-TER and DeltaPro-CT 
mutants (Figure 3E), suggesting that these 
sequences play a role in the ability of TER and 
CT domains of affecting anchorage-indepen-
dent growth.
Overall, these data show that the tyrosines 
inserted in the EPLYA and EGLYA sequences in 
the TER module have an important role in the 
inhibition of tumor cell migration and of anchor-
age-independent growth. In contrast, the pro-
line rich region in the CT domain is mainly rele-
vant for inhibition of cell proliferation, while less 
involved in directional migration or anchorage-
independent growth. Thus, using different 
assays, we were able to dissect the functions of 
tyrosine residues in the EPLYA and EGLYA 
sequences and of the second proline-rich 
stretch, ascribing to these three short peptides 
the ability of acting as negative regulators of 
cell migration and proliferation. These results 
suggest that these short peptides might poten-
tially be used as tumor inhibitory molecules in 
the next future.
TER and CT regions share a common signa-
ture with 140Cap FL
The results shown here indicate that the TER 
and CT proteins are both equally effective in 
down-regulating tumor cell properties, at the 
same extent of the p140Cap FL. To investigate 
whether the three proteins can act through 
common pathways we performed a global gene 
profiling by microarray analysis. Comparison of 
genes modulated by expression of FL, TER and 
CT resulted in 105 commonly down-regulated 
and 128 commonly up-regulated genes (Figure 
4A). As shown in the Venn diagrams, a stronger 
intersection was observed between FL and TER 
than between FL and CT, both for down and up 
regulated genes.
CT and TER) were created with the help of the on-line tool Venny (http://bioinfogp.cnb.csic.es/tools/venny/index.
html). B. The genes modulated in at least one condition in the three GO Biological Processes level 5 (BP5) (left 
panel: Regulation of Signal Transduction; medium panel: Positive Regulation of Cell Proliferation; right panel: Cell 
Migration) were selected to create expression matrices containing the log fold change of the expression of each 
gene in FL, TER and CT compared to Mock. The matrices were then loaded in Tigr MultiExperiment Viewer (TmeV 
version 4.6.1, http://www.tm4.org/mev/) to generate heatmaps by means of hierarchical clustering.
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(BP5) were commonly overrepresented in the 
lists of modulated genes in cells expressing FL, 
TER and CT. We further selected those genes 
modulated in at least one condition and 
involved in regulation of signal transduction 
(GO0009966) (Figure 4B), positive regulation 
of cell proliferation (GO0008284) (Figure 4C) 
and cell migration (GO0016477) (Figure 4D). 
The expression pattern of these genes were 
analyzed together to create expression matri-
ces containing the log fold change of their 
expression in FL, TER and CT compared to 
Mock cells. This bioinformatic analysis shows 
that FL, TER and CT expression leads to down 
or up-regulation of a pattern of common genes, 
with FL and TER profiles more similar to one 
another, respect to CT.
We have already shown that p140Cap, TER and 
CT have similar ability in down-regulating bio-
chemical activities inside the cells, such as Src 
kinase activation. Deeper analysis of the signa-
tures specific for p140Cap, TER and CT domains 
will offer the possibility to explore the molecu-
lar mechanisms underlying the ability of 
p140Cap and of its regions to inhibit tumor 
properties at the level of gene expression, 
opening the perspective of further elucidating 
the pathways modulated by their expression.
Conclusions
In this work we have dissected the modular 
structure of p140Cap, providing evidence that 
the expression of the TER and CT regions of 
p140Cap is sufficient to impair proliferation, 
migration and in vivo growth of breast and 
colon tumor cells at a similar extent of the FL 
protein. Mutagenesis analysis has shown that 
in both TER and CT domains specific amino 
acid sequences can be involved in the control 
of cell migration and cell proliferation. Indeed, 
we have identified three short sequences that 
are relevant for the negative control of cell pro-
liferation and migration (the EPLYA and EGLYA 
sequences and the second proline-rich stretch). 
Moreover gene expression profiling provides 
evidence of the existence of a common signa-
ture of down-regulated and up-regulated genes 
among FL, TER and CT expressing cells. In con-
clusion, this work represents the first attempt 
to identify short relevant regions that retain 
p140Cap inhibitory properties in tumor cells. In 
the next future it is conceivable to look for pep-
tide sequences within these regions to produce 
small molecules with therapeutic potential.
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